文献速递浆细胞疾病造血干细胞移植与细胞治疗

内源性T细胞全景被CAR-T细胞治疗重塑并预测多发性骨髓瘤治疗反应

The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma.
PubMed 文献 · Leukemia · 2025-09-19

本研究在多发性骨髓瘤患者接受抗BCMA CAR-T细胞治疗过程中,以单细胞分辨率探究CAR-T细胞与免疫微环境的共进化动态。研究发现CAR-T治疗深刻重塑内源性T细胞全景,并识别出一种预测不良治疗结局的新型过渡性CD8+ T细胞群体。靶向TIM3/GAL9相互作用可能减轻T细胞耗竭、凋亡及持久性不足,为优化T细胞免疫治疗提供方向。

要点

  • CAR-T治疗重塑内源性T细胞全景,出现预测不良结局的过渡性CD8+ T细胞群体。
  • 该群体出现伴随内源性T细胞库耗竭及功能性T细胞亚群组成演变。
  • 靶向TIM3/GAL9可能减轻T细胞耗竭、凋亡及持久性不足。

核心结论

  • CAR-T细胞治疗重塑内源性T细胞全景,诱导的过渡性CD8+ T细胞群体预测不良治疗结局,靶向TIM3/GAL9相互作用可能减轻T细胞耗竭、凋亡及持久性不足。

研究设计与样本

  • 在多发性骨髓瘤患者接受抗BCMA CAR-T细胞治疗过程中,以单细胞分辨率研究CAR-T细胞与免疫微环境的共进化动态。

主要发现

  • 识别出一种预测不良治疗结局的新型过渡性CD8+ T细胞群体。
  • 该过渡性CD8+ T细胞群体的出现与内源性T细胞库耗竭及功能性T细胞亚群组成演变同时发生。
  • CAR-T细胞治疗诱导的内源性T细胞区室变化可能促成免疫能力不足和肿瘤控制不佳。

临床怎么用

  • 作者认为靶向TIM3/GAL9相互作用可能减轻T细胞耗竭、凋亡及持久性不足,为优化T细胞癌症免疫治疗提供有前景的途径。
  • 作者提出一个评估和调控免疫系统「里程」的框架,作为预测标志物和治疗机会,以防止重复免疫治疗即使靶向不同抗原也变得越来越不成功。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

While most patients initially respond to CAR-T cell treatment, responses often are not durable and subsequent lines of immunotherapy show diminishing success. In this study, we investigated the co-evolutionary dynamics between CAR-T cells and the immune microenvironment in myeloma patients undergoing anti-BCMA CAR-T cell therapy at single-cell resolution. Our findings highlight the transformative impact of CAR-T cell treatment on the endogenous T cell landscape. We identify a novel transitional CD8 + T cell population that is predictive of poor treatment outcomes. The emergence of this population coincides with the depletion of the endogenous T cell repertoire and compositional evolution of functional T cell subsets. These changes in the endogenous T cell compartment induced by CAR-T cell therapy may contribute to inadequate immune capacity and tumor control. Our findings highlight the potential of targeting TIM3/GAL9 interactions to mitigate T cell exhaustion, apoptosis and lack of persistence, offering promising avenues for optimizing T cell-based cancer immunotherapies. We provide a framework for assessing and manipulating the 'mileage' of the immune system as predictive marker and therapeutic opportunity to prevent repeated immunotherapies from becoming increasingly less successful, even when targeting distinct antigens.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Frede J, Poller JC, Shi K, et al. The endogenous T cell landscape is reshaped by CAR-T cell therapy and predicts treatment response in multiple myeloma. Leukemia. 2025. PMID: 40973768. doi:10.1038/s41375-025-02766-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。